Minimal residual disease in acute myeloid leukemia: already predicting a safe haven?

@article{Schuurhuis2010MinimalRD,
  title={Minimal residual disease in acute myeloid leukemia: already predicting a safe haven?},
  author={Gerrit J Schuurhuis and Gert Jan Ossenkoppele},
  journal={Expert review of hematology},
  year={2010},
  volume={3 1},
  pages={1-5}
}
Immunophenotypical and/or molecular aberrancies have been known for decades to mark either the majority of or particular subsets of acute lymphocytic leukemia (ALL), acute myeloid leukemia (AML) and chronic myeloid leukemia (CML). In ALL, the relatively homogeneous aberrant immunophenotype as well as the molecular aberrancies covering most cases (reviewed in [1]) have already enabled the early assessment of the value of these aberrancies for the detection of residual disease after therapy and… CONTINUE READING

References

Publications referenced by this paper.
Showing 1-10 of 31 references

Frequent instability of type I and II aberrations between diagnosis and relapse observed in pediatric AML ; implications for targeted therapy and MRD detection

  • C Bachas, GJ Schuurhuis, Hollink IHIM
  • Blood
  • 2009

Specific flow cytometric detection of leukemic stem cells in acute myeloid leukemia predicts prognosis in remission bone marrow

  • M Terwijn, A Kelder, AP Rutten
  • Blood 114,
  • 2009

with limited differentiation and NPM 1 type A mutation : a new biologically defined entity

  • D Cilloni, A Renneville, F Hermitte
  • 2009

High leukemic cell frequency in remission bone marrow predicts poor outcome in acute myeloid leukemia

  • M Terwijn, A Kelder, AP Rutten
  • Blood
  • 2008

Similar Papers

Loading similar papers…